Why VK2735’s Dual GLP-1/GIP Action Could Disrupt the Weight Loss Market Viking’s GLP-1 drug is named VK2735. It’s a dual GLP-1/GIP receptor agonist, similar to tirzepatide. GLP-1 (glucagon ...
The company plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the first half of 2025. About GLP-1 and Dual GLP-1/GIP Agonists Activation of the glucagon-like ...
Viking Therapeutics has signed a long-term, $150 million strategic partnership with CordenPharma to support the development and commercialization of VK2735, its dual GLP-1/GIP receptor agonist for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback